NEUROCRINE BIOSCIENCES INC Increase (Decrease) in Other Current Assets
NEUROCRINE BIOSCIENCES INC (NBIX) reported Increase (Decrease) in Other Current Assets of $2.18 million for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-04.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentAssets · last filed 2019-11-04
- NEUROCRINE BIOSCIENCES INC increase (decrease) in other current assets for the quarter ending 2019-09-30 was $2.20M.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in other current assets for the quarter ending 2019-06-30 was -$2.13M, a 186.75% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in other current assets for the quarter ending 2019-03-31 was $2.11M, a 378.46% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in other current assets for the quarter ending 2018-09-30 was -$180.00K, a 109.58% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in other current assets for fiscal 2017 was $3.75M.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in other current assets for fiscal 2016 was -$1.79M, a 466.26% decline from fiscal 2015.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in other current assets for fiscal 2015 was $489.00K.
| Period end | Increase (Decrease) in Other Current Assets 3 month | Increase (Decrease) in Other Current Assets 3 month as first filed | Increase (Decrease) in Other Current Assets 6 month | Increase (Decrease) in Other Current Assets 9 month | Increase (Decrease) in Other Current Assets 9 month as first filed | Increase (Decrease) in Other Current Assets 12 month |
|---|---|---|---|---|---|---|
| 2019-09-30 | $2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $70.00K derived: sum of 2 quarters · filed 2019-11-04 | $2.18M 10-Q · filed 2019-11-04 | |||
| 2019-06-30 | -$2.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-29 | -$18.00K 10-Q · filed 2019-07-29 | ||||
| 2019-03-31 | $2.11M 10-Q · filed 2019-04-29 | |||||
| 2018-09-30 | -$180.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $2.27M derived: sum of 2 quarters · filed 2019-11-04 | $2.71M 10-Q · filed 2019-11-04 | $6.84M 10-Q · filed 2018-11-05 | $2.15M derived: sum of 4 quarters · filed 2019-11-04 | |
| 2018-06-30 | $2.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-29 | $2.89M 10-Q · filed 2019-07-29 | $2.33M derived: sum of 3 quarters · filed 2019-07-29 | $4.20M derived: sum of 4 quarters · filed 2019-07-29 | ||
| 2018-03-31 | $441.00K 10-Q · filed 2019-04-29 | $750.00K 10-Q · filed 2018-04-30 | -$127.00K derived: sum of 2 quarters · filed 2019-04-29 | $1.75M derived: sum of 3 quarters · filed 2019-04-29 | $4.19M derived: sum of 4 quarters · filed 2019-04-29 | |
| 2017-12-31 | -$568.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $1.31M derived: sum of 2 quarters · filed 2018-11-05 | $3.75M derived: sum of 3 quarters · filed 2018-11-05 | $3.75M 10-K · filed 2018-02-13 | ||
| 2017-09-30 | $1.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $4.32M derived: sum of 2 quarters · filed 2018-11-05 | $4.32M 10-Q · filed 2018-11-05 | $2.56M derived: sum of 4 quarters · filed 2018-11-05 | ||
| 2017-06-30 | $2.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-31 | $2.44M 10-Q · filed 2018-07-31 | $680.00K derived: sum of 3 quarters · filed 2018-07-31 | $961.00K derived: sum of 4 quarters · filed 2018-07-31 | ||
| 2017-03-31 | $0.00 10-Q · filed 2018-04-30 | -$1.76M derived: sum of 2 quarters · filed 2018-04-30 | -$1.48M derived: sum of 3 quarters · filed 2018-04-30 | |||
| 2016-12-31 | -$1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | -$1.48M derived: sum of 2 quarters · filed 2018-02-13 | -$1.79M 10-K · filed 2018-02-13 | |||
| 2016-09-30 | $281.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | -$34.00K 10-Q · filed 2017-11-01 | ||||
| 2016-06-30 | -$315.00K 10-Q · filed 2017-08-03 | |||||
| 2015-12-31 | -$1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $187.00K derived: sum of 2 quarters · filed 2018-02-13 | $489.00K 10-K · filed 2018-02-13 | |||
| 2015-09-30 | $1.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | $1.55M 10-Q · filed 2016-11-02 | ||||
| 2015-06-30 | $302.00K 10-Q · filed 2016-08-03 | |||||
| 2014-09-30 | $1.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-29 | $1.47M 10-Q · filed 2015-10-29 | ||||
| 2014-06-30 | $196.00K 10-Q · filed 2015-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |